Comparative study of the developmental patterns of vasopressin, glucagon, angiotensin II, and alpha 1-adrenergic receptors in the liver of developing and adult hypothyroid rats.
The effects of propylthiouracil (PTU) treatment on vasopressin, angiotensin II, glucagon and alpha 1-adrenergic receptors in both developing and adult rats were studied in liver membrane preparations by measuring the binding of the following ligands: [3H][8-lysine]vasopressin, [3H]Sar-angiotensin II, [125I]glucagon and [3H]prazosin, and in the case of glucagon, by measuring adenylate cyclase activation. Whatever the ligand used, in young as well as in adult animals, PTU treatment led to a similar reduction (about 50%) in the maximal number of binding sites (Bmax), without significant changes in the apparent dissociation constant (KD) of labeled hormone for its specific receptor. In normal adult animals, thyroxine treatment, i.e. hyperthyroidism, had an opposite effect on the Bmax (25-50% increase), without changes in the KD. In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of thyroxine; consequently they were directly related to thyroid deficiency and not to toxic effects of PTU. Moreover, the abnormalities resulting from induced hypothyroidism were reversible. In developing and adult hypothyroid rats, neither basal, NaF-, nor Gpp(NH)p-stimulated adenylate cyclase activities were significantly affected. Glucagon-sensitive adenylate cyclase activity seemed to be slightly increased (by about 15%), without changes in the apparent activation constant (Kact). These results are considered in parallel with findings on plasmatic glucagon and vasopressin levels, compared with similar previous reports related to renal vasopressin receptors, and discussed with respect to unpublished observations concerning hepatic responsiveness to glycogenolytic hormones in young and adult rats with induced hypothyroidism.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000367:Age Factors; D000818:Animals; D002462:Cell Membrane / Q000502:physiology; D019204:GTP-Binding Proteins / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D007037:Hypothyroidism / Q000503:physiopathology*; D008099:Liver / Q000502:physiology*; D008236:Lypressin / Q000378:metabolism; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D011945:Receptors, Angiotensin / Q000502:physiology*; D011964:Receptors, Gastrointestinal Hormone / Q000502:physiology*; D018027:Receptors, Glucagon; D017483:Receptors, Vasopressin; D013974:Thyroxine / Q000494:pharmacology
D011942:Receptors, Adrenergic, alpha; D011945:Receptors, Angiotensin; D011964:Receptors, Gastrointestinal Hormone; D018027:Receptors, Glucagon; D017483:Receptors, Vasopressin; D008236:Lypressin; D005934:Glucagon; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D013974:Thyroxine